Promatix, a biotechnology company, has been awarded a grant from Innovate UK to support the development of its cis-bispecific antibody-drug conjugate (ADC) programme. The grant will enable the company to advance this novel therapeutic approach, which is designed to improve the precision and efficacy of cancer treatments.
The cis-bispecific ADC technology aims to target two different antigens on the same cell, potentially enhancing tumor specificity and reducing off-target effects. This approach represents a significant innovation in the field of oncology, as traditional ADCs typically target a single antigen.
Innovate UK is the UK's innovation agency, providing funding and support to businesses to drive scientific and technological advancements. The grant to Promatix underscores the potential of this technology to contribute to the development of next-generation cancer therapies.
Promatix has not disclosed the exact amount of the grant or the specific milestones associated with the funding. However, the company has expressed enthusiasm about the opportunity to accelerate its research and development efforts.
